• Chudamani B
• Dr.Subhas S Karki

All the compounds (CH-69 to CH-84) were evaluated for their cytostatic activity against human HeLa cervix carcinoma cells, human CEM CD4þ T-lymphocytes as well as murine L1210 cells. All assays were performed in 96-well microtiter plates. To each well were added (5-7.5) x 104 tumor cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 37 ºC in a humidified CO2-controlled atmosphere. At the end of the incubation period, the cells were counted in a Coulter counter. The IC50 (50% inhibitory concentration) was defined as the concentration of the compound that inhibited cell proliferation by 50%. The Cytotoxicity and antiviral activity of a new series of 2-arylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-2H-chromen-2-one against different MDCK cell cultures, HELa cell cultures, Vero cell cultures, CRFK cell cultures is reported. Among the tested compounds, Inhibitory effects of compounds (CH-69 to CH-84) on the proliferation of murine leukemia cells (L1210) and human T-lymphocyte cells (CEM) and human cervix carcinoma cells (HeLa).

HeLa, MDCK, CRFK, thymidine kinase-deficient (TK-) HSV-1 Kos strain, herpes simplex virus.

"Synthesis of Novel Levamisole derivatives for their anticancer and antiviral activity", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 9, page no.f370-f383, September-2022, Available :http://www.jetir.org/papers/JETIR2209571.pdf

"Synthesis of Novel Levamisole derivatives for their anticancer and antiviral activity", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 9, page no. ppf370-f383, September-2022, Available at : http://www.jetir.org/papers/JETIR2209571.pdf